Company Interview / Radiopharm dials up US$5M investment

Paul Hopper of Radiopharm Theranostics (ASX: RAD) discusses the company's strengthened ties with Nasdaq-listed Lantus Holdings, which recently increased its stake to 12.1% through a US $5 million investment. Paul sees this as a strong endorsement for Radiopharm's assets and management.

He outlines the application of the funding towards clinical drug trials, primarily aimed at utilising radioisotopes for tumour targeting. Radiopharm's focus is both diagnostic, illuminating cancer, and therapeutic, aiming to destroy cancer cells.

Paul highlights the lengthy process of drug approval but remains optimistic about future FDA approvals, especially with emerging success in prostate cancer treatments. He points to initial challenges like post-IPO downturns but notes recent successful capital raises and Nasdaq listing, boosting the company’s momentum.